Sameer Farouk Sait
Overview
Explore the profile of Sameer Farouk Sait including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farouk Sait S, Tang K, Angus S, Brown R, Sun D, Xie X, et al.
Proc Natl Acad Sci U S A
. 2025 Jan;
122(1):e2407745121.
PMID: 39793045
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas and the primary cause of mortality in patients with neurofibromatosis type 1 (NF1). These malignancies develop within preexisting benign lesions called...
2.
Farouk Sait S, Kernan N, Klein E, Spitzer B, Fein Levy C, Fish J, et al.
Pediatr Blood Cancer
. 2024 Sep;
71(11):e31297.
PMID: 39217426
Background: The prognosis for patients with central nervous system (CNS) retinoblastoma (RB) (trilateral or stage 4b metastatic RB) treated with high-dose chemotherapy and autologous stem cell transplant (HDC-ASCT) remains poor....
3.
Mankuzhy N, Tringale K, Dunkel I, Farouk Sait S, Souweidane M, Khakoo Y, et al.
Pediatr Blood Cancer
. 2024 Mar;
71(5):e30929.
PMID: 38430472
Background: Re-irradiation (reRT) increases survival in locally recurrent diffuse intrinsic pontine glioma (DIPG). There is no standard dose and fractionation for reRT, but conventional fractionation (CF) is typically used. We...
4.
Farouk Sait S, Fischer C, Antal Z, Spatz K, Prince D, Ibanez K, et al.
Pediatr Blood Cancer
. 2023 May;
:e30410.
PMID: 37158537
Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors (TKIs) are increasingly being used off label in pediatrics. Long-term safety data are limited, and serious toxicities unique to pediatrics may emerge....
5.
Farouk Sait S, Giantini-Larsen A, Tringale K, Souweidane M, Karajannis M
Curr Neurol Neurosci Rep
. 2023 Mar;
23(4):185-199.
PMID: 36881254
Purpose Of Review: Pediatric low-grade gliomas and glioneuronal tumors (pLGG) account for approximately 30% of pediatric CNS neoplasms, encompassing a heterogeneous group of tumors of primarily glial or mixed neuronal-glial...
6.
ODonohue T, Farouk Sait S, Glade Bender J
Curr Opin Pediatr
. 2022 Nov;
35(1):41-47.
PMID: 36377257
Purpose Of Review: The fields of precision medicine and cancer genomics in pediatric oncology are rapidly evolving. Novel diagnostic tools are critical in refining cancer diagnoses, stratifying patient risk, and...
7.
Farouk Sait S, Bernot M, Klein E, Abramson D, Francis J, Gilheeney S, et al.
Pediatr Blood Cancer
. 2022 Aug;
70(1):e29921.
PMID: 35934994
Background: Stage 4a metastatic retinoblastoma (RB) is curable with intensive multimodality therapy including myeloablative chemotherapy with autologous stem cell transplant (HDC-ASCT) and involved field radiation therapy (IFRT). To our knowledge,...
8.
Brown R, Farouk Sait S, Dunn G, Sullivan A, Bruckert B, Sun D
Brain Sci
. 2022 Jun;
12(6).
PMID: 35741605
Neurofibromatosis Type 1 (NF1) is one of the most common genetic tumor predisposition syndromes, affecting up to 1 in 2500 individuals. Up to half of patients with NF1 develop benign...
9.
Rosenberg T, Yeo K, Mauguen A, Alexandrescu S, Prabhu S, Tsai J, et al.
Neuro Oncol
. 2022 Apr;
24(11):1964-1975.
PMID: 35397478
Background: The prognosis for patients with pediatric high-grade glioma (pHGG) is poor despite aggressive multimodal therapy. Objective responses to targeted therapy with BRAF inhibitors have been reported in some patients...
10.
Farouk Sait S, Karajannis M
Neuro Oncol
. 2022 Feb;
24(6):984-985.
PMID: 35171291
No abstract available.